PEDIATRICS Vol. 97 No. 5 May 1996, pp. 738-739
This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vlacha, V.
Right arrow Articles by Peter, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vlacha, V.
Right arrow Articles by Peter, G.

Recurrent Thrombocytopenic Purpura After Repeated Measles-Mumps-Rubella Vaccination

Vasiliki Vlacha MD1, Edwin N. Forman MD1, Dan Miron MD2, and Georges Peter MD2

1 Division of Pediatric Hematology-Oncology
2 Division of Pediatric Infectious Diseases, Department of Pediatrics, Rhode Island Hospital, Brown University School of Medicine, Providence, RI 02903

In a review of adverse events associated with childhood vaccines, the Vaccine Safety Committee of the Institute of Medicine (IOM) in 1993 concluded that a causal relationship exists between live-virus measles-mumps-rubella (MMR) vaccination and thrombocytopenia.1 This finding was based on case reports of temporally associated onset of acute thrombocytopenia purpura and MMR vaccination,2,3 population-based surveillance of adverse vaccine reactions in Sweden4 and Finland,5 and demonstrated decreases in platelet concentrations after measles vaccination with the Edmonston B strain.6 The IOM committee also noted that children with prior histories of thrombocytopenia may be at an increased risk of recurrence after MMR vaccination.

Submitted on May 19, 1995
Accepted on August 3, 1995




This article has been cited by other articles:


Home page
 Arch. Dis. Child.Home page
A. C Bibby, A. Farrell, M. Cummins, and M. Erlewyn-Lajeunesse
Is MMR immunisation safe in chronic Idiopathic thrombocytopenic purpura?
Arch. Dis. Child., April 1, 2008; 93(4): 354 - 355.
[Full Text] [PDF]

Home page
 Arch. Dis. Child.Home page
J. Stowe, G. Kafatos, N. Andrews, and E. Miller
Idiopathic thrombocytopenic purpura and the second dose of MMR
Arch. Dis. Child., February 1, 2008; 93(2): 182 - 183.
[Full Text] [PDF]

Home page
 Arch. Dis. Child.Home page
E Miller, P Waight, C P Farrington, N Andrews, J Stowe, and B Taylor
Short report: Idiopathic thrombocytopenic purpura and MMR vaccine
Arch. Dis. Child., March 1, 2001; 84(3): 227 - 229.
[Abstract] [Full Text]

Home page
 J. Virol.Home page
F. R. Brennan, T. Bellaby, S. M. Helliwell, T. D. Jones, S. Kamstrup, K. Dalsgaard, J.-I. Flock, and W. D. O. Hamilton
Chimeric Plant Virus Particles Administered Nasally or Orally Induce Systemic and Mucosal Immune Responses in Mice
J. Virol., February 1, 1999; 73(2): 930 - 938.
[Abstract] [Full Text]